Results 111 to 120 of about 198,039 (308)

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. [PDF]

, 2019
The clinical deployment of immune checkpoint inhibitors (ICIs) has created a tandem drive for the identification of biomarkers linked to benefit. Comprehensive genomic profiling was performed to evaluate the frequency of genomic biomarkers of ICI ...
Ali, Siraj M, Ang, Celina, Fabrizio, David, Goodman, Aaron, Klempner, Samuel J, Kurzrock, Razelle, Madison, Russell, Millis, Sherri Z, Ross, Jeffrey S, Severson, Eric A, Suh, James   +10 more
core   +1 more source

Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021

International Journal of Cancer, EarlyView.
What's New? Liver metastasis is an indicator of life expectancy for patients with advanced uveal melanoma (UM). Data on anticipated survival time following the diagnosis of liver metastasis, however, is lacking. The present study analyzed long‐term survival among UM patients who lived three or more years after liver metastases were diagnosed.
Jona Laukhuf, Lisa Wiens, Gerd Grözinger, Helmut Dittmann, Karolin Thiel, Ulrike Leiter, Teresa Amaral, Lena Nanz, Lukas Flatz, Markus Reitmajer, Andrea Forschner   +10 more
wiley   +1 more source

Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome [PDF]

, 2018
Stevens-Johnson syndrome is a rare adverse cutaneous drug reaction characterized by epidermal detachment of
Al-Omari, Ahmed, Rancour, Elizabeth A., Shah, Kishan M.   +2 more
core  

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

International Journal of Cancer, EarlyView.
What's New? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Carmen González Arenas, Zhenghong Chen, Wen Cheng Yu, Tony S. K. Mok   +14 more
wiley   +1 more source

Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience

Advances in Radiation Oncology
Purpose: The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiation therapy (RT), and adjuvant pembrolizumab.
Thais Tison, MD, Pierre Loap, MD, Emilie Arnaud, MD, Kim Cao, MD, Solene Bringer, MD, Manon Kissel, MD, Safia Maaradji, MD, Juliette Mainguene, MD, Jean-Yves Pierga, MD, PhD, Florence Lerebours, MD, Anne Vincent-Salomon, MD, PhD, Mariana Mirabelle, MD, Francois-Clement Bidard, MD, PhD, Delphine Loirat, MD, PhD, Youlia M. Kirova, MD   +14 more
doaj   +1 more source

PEMBROLIZUMAB-INDUCED HYPOPHISITIS IN A PATIENT WITH UNDERLYING HYPOTHYROIDISM PRESENTING AS ADRENAL CRISIS

, 2023
Abdullah Shamshir Abd Mokti, Raja Nurazni Raja Azwan   +1 more
openalex   +2 more sources

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, EarlyView.
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

Organ‐sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision‐making

International Journal of Cancer, EarlyView.
Abstract Deficiency in DNA mismatch repair (dMMR) is a common pathway of carcinogenesis across different tumor types and confers a characteristic microsatellite instability‐high (MSI‐H) molecular phenotype. The MSI‐H/dMMR phenotype may arise from an inherited pathogenic variant in the context of Lynch syndrome and is most frequently observed in ...
Martin Duval, Antoine Dardenne, Thomas Samaille, Leo Mas, Jérémie H. Lefèvre, Xavier Dray, Mathilde Wagner, Romain Cohen, Thierry André   +8 more
wiley   +1 more source

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma

, 2022
Dirk Schadendorf, Reinhard Dummer, Caroline Robert, Antoni Ribas, Ryan J. Sullivan, Timothy J. Panella, Meredith McKean, Edgardo S. Santos, Kimberli J. Brill, Anna Polli, Alessandra di Pietro, Paolo A. Ascierto   +11 more
openalex   +1 more source

Immunotherapy in advanced gastroesophageal cancers: A meta‐analysis of sex‐based outcomes in overall survival

International Journal of Cancer, EarlyView.
What's New? Immune checkpoint inhibitors (ICIs) improve survival in advanced gastroesophageal cancer (GEC), but their benefits may differ by sex. Little is known, however about the impact of sex‐related immune differences on ICI efficacy. In this meta‐analysis, sex‐specific outcomes of ICI therapy were evaluated in advanced GEC, encompassing both ...
Michael Masetti, Fausto Petrelli, Filippo Pietrantonio, Sylvie Lorenzen, Alberto Giovanni Leone   +4 more
wiley   +1 more source